NASDAQ:KPTI - Karyopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics Inc (NASDAQ:KPTI) issued its earnings results on Monday, November, 4th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.17. The firm had revenue of $13.15 million for the quarter, compared to the consensus estimate of $1.61 million. Karyopharm Therapeutics had a negative return on equity of 187.25% and a negative net margin of 909.24%. View Karyopharm Therapeutics' Earnings History.

Karyopharm Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Karyopharm Therapeutics.

6 equities research analysts have issued 12 month price objectives for Karyopharm Therapeutics' stock. Their forecasts range from $5.00 to $37.00. On average, they expect Karyopharm Therapeutics' share price to reach $22.33 in the next twelve months. This suggests a possible upside of 35.4% from the stock's current price. View Analyst Price Targets for Karyopharm Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Karyopharm Therapeutics.

News headlines about KPTI stock have trended somewhat positive recently, according to InfoTrie. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 1.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Karyopharm Therapeutics.

Karyopharm Therapeutics saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 9,570,000 shares, a drop of 6.8% from the December 15th total of 10,270,000 shares. Based on an average trading volume of 1,260,000 shares, the days-to-cover ratio is currently 7.6 days. Approximately 17.2% of the shares of the company are short sold. View Karyopharm Therapeutics' Current Options Chain.

Some companies that are related to Karyopharm Therapeutics include Evotec (EVTCY), BridgeBio Pharma (BBIO), Allakos (ALLK), United Therapeutics (UTHR), Nektar Therapeutics (NKTR), FibroGen (FGEN), SAGE Therapeutics (SAGE), Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Blueprint Medicines (BPMC), HUTCHISON CHINA/S (HCM), Deciphera Pharmaceuticals (DCPH), Ultragenyx Pharmaceutical (RARE), PTC Therapeutics (PTCT) and Myokardia (MYOK).

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Bristol-Myers Squibb (BMY), Exelixis (EXEL), Micron Technology (MU), Alibaba Group (BABA), Caladrius Biosciences (CLBS), Celgene (CELG), GW Pharmaceuticals PLC- (GWPH) and Sorrento Therapeutics (SRNE).

Karyopharm Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Private Capital Advisors Inc. (0.17%), Campbell & CO Investment Adviser LLC (0.06%) and First Midwest Bank Trust Division (0.04%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Institutional Ownership Trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division and Private Capital Advisors Inc.. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman and Sharon Shacham. View Insider Buying and Selling for Karyopharm Therapeutics.

KPTI stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $16.50.

Karyopharm Therapeutics has a market capitalization of $1.04 billion and generates $30.34 million in revenue each year. The company earns $-178,410,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.View Additional Information About Karyopharm Therapeutics.

The official website for Karyopharm Therapeutics is http://www.karyopharm.com/.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]